Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 of Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of TPX-0022 in Adult Subjects With Locally Advanced or Metastatic NSCLC, Gastric Cancer, or Solid Tumors Harboring Genetic Alterations in MET

NCT03993873 is registered in ClinicalTrials.gov with Turning Point Therapeutics, Inc. as lead sponsor.

NCT NCT03993873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03993873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 of Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of TPX-0022 in Adult Subjects With Locally Advanced or Metastatic NSCLC, Gastric Cancer, or Solid Tumors Harboring Genetic Alterations in MET
Lead sponsor
Turning Point Therapeutics, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 5, 2019
Completion date
March 3, 2027
Enrollment
95 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, met gene alterations, metastatic solid tumors